Quantcast

Latest Myeloproliferative disease Stories

2009-08-03 12:07:50

 La Jolla Institute for Allergy & Immunology researchers studying an enzyme believed to play a role in allergy onset, instead have discovered its previously unknown role as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. Myeloproliferative diseases are a group of disorders characterized by an overproduction of blood cells by the bone marrow and include chronic myeloid leukemia. Lymphoma and leukemia are cancers of the...

2009-06-22 21:05:00

MELBOURNE, Australia, June 22 /PRNewswire/ -- Cytopia Ltd (ASX: CYT) announced today that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) for its novel, potent orally active JAK2 inhibitor CYT387. Following FDA review, the company intends to commence a Phase I/II trial for CYT387 in patients with myelofibrosis, a serious progressive and chronic condition where scar tissue develops in the bone marrow. CYT387 is expected to be the...

2009-05-04 01:30:00

MARSEILLE, France, May 4 /PRNewswire-FirstCall/ -- Ipsogen SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, the manufacturing and the commercialization of diagnostic assays for breast cancer and leukemia, today announces the signature of an agreement with ARUP Laboratories to offer JAK2 molecular diagnostic testing in the USA. According to the terms of the agreement, Ipsogen grants ARUP, a national clinical and anatomic pathology...

2009-03-23 18:42:00

MELBOURNE, Australia, March 23 /PRNewswire/ -- Cytopia Limited (ASX: CYT) today announced that it will present data on its JAK2 program at the American Chemical Society Spring meeting, currently underway in Salt Lake City, Utah, USA. Dr Tracy Nero, Senior Scientist at Cytopia, will be presenting the poster in the Division of Medicinal Chemistry's general poster session on Wednesday, March 25, 2009 from 7:00 PM to 9:00 PM (US ET), Salt Palace Convention Center, Hall 1. The poster, entitled...

2009-03-15 16:03:13

 Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have shown for the first time that a tendency to develop some blood disorders may be inherited. Their research, published online today in Nature Genetics, identifies a common genetic sequence abnormality that enhances the likelihood of acquiring a mutation in a gene linked to certain blood diseases.The investigators carried out a genome-wide study to identify inherited DNA sequence changes that frequently occur in patients...

2009-01-12 11:30:00

MARSEILLE, France, January 12 /PRNewswire-FirstCall/ -- IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products during the fourth quarter of 2008, that expand its leukemia molecular diagnostic portfolio: - FusionQuant BCR-ABL IVD kit, used in the the detection and monitoring of chronic myeloid leukemias (CML), is a new CE marked expanded version of...

2009-01-06 15:25:00

EMERYVILLE, Calif., Jan. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has acquired an option to license rights to SB1518, an orally available, potent, and selective inhibitor of Janus Kinase 2 (JAK2), and SB1578, also a JAK2 inhibitor, from S*BIO Pte Ltd based in Singapore. Under the terms of the agreement, Onyx has obtained option rights to exclusively develop and commercialize SB1518 (designated by Onyx as ONX 0803) and SB1578 (designated by...

2008-12-18 18:00:00

SINGAPORE, Dec. 19 /PRNewswire/ -- S*BIO Pte Ltd today announced that it has signed a collaboration agreement with Tan Tock Seng Hospital (TTSH) in Singapore, to evaluate the effects of its JAK2 inhibitor, SB1518, on biological samples from patients with myeloproliferative neoplasms (MPNs). S*BIO scientists will work closely with TTSH investigators to evaluate the potential therapeutic effects of SB1518 on diseased blood cells isolated from patients with MPN, and to validate the utility of...

2008-12-07 21:03:00

MELBOURNE, Australia, Dec. 7 /PRNewswire/ -- Data on Cytopia's (ASX: CYT) JAK2 inhibitor CYT387 will be presented at the 50th American Society of Hematology conference in San Francisco. The talk will be presented by Dr Thomas Bumm of Oregon Health and Sciences University and will overview the study of CYT387 in an in- vivo model of myeloproliferative disorders. Full presentation details: Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD 7am US PST, Tuesday...

2008-12-06 17:00:00

SAN FRANCISCO, Dec. 6 /PRNewswire-USNewswire/ -- Four studies highlighting late-breaking research advances in the treatment of cancer and sickle cell disease will be presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA. Results from a study examining the ability of an investigational agent to improve endothelial dysfunction, a malfunction in the inner lining of blood vessels, in patients with sickle cell disease will be featured at a press...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related